To enable progress in treatment of generative conditions by gaining control of a major barrier: the immune system.
SEKRIS was founded to commercialize a revolutionary technology originally developed at Loma Linda University. SEKRIS has assembled a world class team of professionals and academic partners to continue the rapid advancement of the technology towards human trials.
While the reasons for the increase in the rate of degenerative diseases are not fully understood, the inability to effectively control the immune system plays an important role. Any advances in treatment of these diseases and conditions and the subsequent regeneration of damaged tissues must consider means to control the immune system.
SEKRIS employs apoptotic DNA immunotherapy (ADI) to trigger the body to create apoptotic cells. When the immune system processes an apoptotic cell, it recognizes that the cell was not damaged by a dangerous threat. SEKRIS utilizes these naturally occurring cells to deliver signals which instruct the immune system to tolerate the tissue which is mistakenly under attack.